7 New Insights to Preventing Off-Label Sales Promotion


I was invited to present at a recent meeting of the AdvaMed Emerging Growth Company Council. My presentation on “Preventing Off-Label Sales Promotion” generated much interesting discussion. One passionate individual debated that sales people were not to blame and that they were simply at the receiving end of internal strategies and dictates. While studies support that corporate strategies were to blame in the past, lawyers think that is becoming more rare, especially in pharma.

View the slides of my presentation here and share your thoughts:

Key Questions

  • Do you think sales is simply an easy target for government investigators pursuing illegal off-label activity?
  • Or, do you think sales is still on the receiving end of bad direction? Is the same true in pharma and medical devices or is it different?

To keep up with the best in Good Promotional Practices, subscribe to our GPP RSS feed, our Facebook page, our Twitter stream or our LinkedIn group.

2 responses to “7 New Insights to Preventing Off-Label Sales Promotion

  1. Pingback: Pharma Petitions FDA for Binding Off-Label Rules | Good Promotional Practices

  2. Pingback: FDA Ready to Rumble: 3 To Dos for CEOs | Good Promotional Practices

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s